• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Medical Gas Research >Revisiting the expanded use of hyperbaric oxygen therapy for treatment of resistant migraines
【24h】

Revisiting the expanded use of hyperbaric oxygen therapy for treatment of resistant migraines

机译：重新探讨高压氧疗法在耐药性偏头痛治疗中的广泛应用

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

There are currently 13 indications approved by the U.S. Food and Drug Administration for use of hyperbaric oxygen therapy. The European Consensus Conference on Hyperbaric Medicine has 28 indications approved for its use. However, neither includes the use of hyperbaric oxygen therapy for neurological conditions such as migraines with aura. Recent research has made the attempt to fully understand the use of hyperbaric therapy in treatment of neurological conditions, but results have so far been inconclusive. We report a 23-year-old female with an 11-year history of migraines with aura who has received inadequate pharmacological treatment for her migraines since she began having them. Migraines have led her to significant loss of function. The patient underwent treatment at 1.5 absolute atmospheres in a hyperbaric chamber Monday through Friday for 1 hour each day for a total of 40 sessions but reported missing a few sessions over the 8-week period. No more than 1 session during a given week was missed and the patient received no other treatments for her migraines throughout this time period. By her 24supth/sup treatment, the patient had only experienced a single migraine with aura but without debilitating pain. The patient stated she had never had a migraine with such little intensity prior to initiation of hyperbaric treatment and did not have to take any days off from work or school. Follow-up at the end of her 40-day treatment period revealed a highly-satisfied patient who had only experienced the single episode of a mild migraine during the entire course of treatment. Thus, we believe that further research needs to be done to realize the full potential of hyperbaric oxygen therapy in the treatment of neurological conditions as this case highlights the potential for using hyperbaric oxygen therapy as prophylaxis against attacks in patients with treatment resistant migraines with aura.
机译：目前，美国食品药品管理局批准了13种高压氧治疗的适应症。欧洲高压医学共识会议已批准使用28种适应症。但是，这两种方法均不包括对神经系统疾病（如先兆偏头痛）使用高压氧疗法。最近的研究已经尝试完全了解高压疗法在神经系统疾病治疗中的应用，但迄今为止结果尚无定论。我们报道了一名具有11年偏头痛先兆病史的23岁女性，自从她患有偏头痛以来，她没有得到足够的药物治疗。偏头痛使她严重丧失功能。周一至周五，患者在高压舱中的1.5个绝对大气压下接受治疗，每天进行1个小时，共40次疗程，但据报告在8周的时间里错过了几次疗程。在给定的一周内，没有错过最多1次疗程，并且在此期间，该患者的偏头痛没有接受其他治疗。通过她的第24次治疗，该患者仅经历了一次先兆偏头痛并伴有先兆但没有使人衰弱。该患者表示，在开始高压治疗之前，她从未有过偏头痛的强度如此之小，也不必休假一天或下班或上学。在为期40天的治疗期结束时进行的随访显示，一名非常满意的患者在整个治疗过程中仅经历了一次轻度偏头痛发作。因此，我们认为，需要进一步的研究来实现高压氧疗法在神经系统疾病治疗中的全部潜力，因为这种情况突显了使用高压氧疗法来预防具有治疗性先兆的偏头痛患者的攻击的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号